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Abstract
Background: Overall response rate to cardiac resynchronization therapy (CRT) is still not 
optimal. The aim of the study was to evaluate the influence of the regional myocardial contra-
ctile reserve during dobutamine infusion in the area of left ventricular (LV) electrode on the 
response rate and reverse remodeling LV in patients receiving CRT.
Methods: Biventricular pacemaker was implanted in 41 consecutive patients (33 men, mean 
age 62 ± 10 years) with LV ejection fraction (LVEF) ≤ 35%, New York Heart Association class III  
and QRS duration ≥ 120 ms. Myocardial contractile reserve was assessed by LV strain du-
ring dobutamine infusion (20 µg/kg/min) using speckle tracking echocardiography. Patients 
were classified as responders if an increase in LVEF ≥ 5% or decrease in end-systolic volume  
≥ 15% was observed after 6 months of CRT.
Results: Twenty-four patients were responders and 17 were non-responders. During dobuta-
mine infusion at a rate of 20 µg/kg/min, responders showed significant increase in regional de-
formation (∆ strain) when compared to non-responders (2.14 ± 2.9 vs. – 0.94 ± 1.74, p = 0.042).  
Patients with increased deformation in the LV lead area during dobutamine stimulation were 
more likely to be responders to CRT compared to patients without increased deformation in this 
area (81% vs. 20%, p = 0.0002). They exhibited significant increase in LVEF (8.8% ± 10.3%  
vs. 0.3% ± 6.4%, p = 0.01). LV electrode localization in viable myocardium was a good pre-
dictor of response to CRT (AUC 0.852, p < 0.0001).
Conclusions: Regional contractile reserve assessed by strain rate echocardiography during 
dobutamine infusion predicts the response to CRT. (Cardiol J 2014; 21, 5: 524–531)
Key words: myocardial contractility, cardiac resynchronization therapy,  
myocardial strain, echocardiography, myocardial viability
Introduction
Cardiac resynchronization therapy (CRT) is 
an important therapeutic option in drug-refractory 
heart failure (HF) of ischemic and non-ischemic 
etiology. CRT reduces symptoms of HF and re-
duces morbidity and mortality. In comparison to 
pharmacological therapy, CRT lowers the hospi-
talization for HF by 52% and leads to relative risk 
reduction in cardiac death of 36–40% [1]. However, 
the overall response rate to CRT is still not opti-
mal. About one third of patients do not respond 
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to CRT. Majority of attempts to solve the issue of 
non-responding patient population is focused on 
the improvement of patient selection and optimi-
zation of device programming after implantation 
[2]. Lead positioning is another factor contributing 
to the therapeutic effect of CRT in the individual 
patient. The optimal site for the positioning of the 
left ventricular (LV) lead is lateral or posterolateral 
vein. Anterior location of LV lead is controversial, 
sub-study from MADIT-CRT trial showed that 
only apical, not anterior location predicted lower 
response to CRT [3]. Similarly, analysis of lead 
location in the REVERSE trial concluded that more 
favorable outcome of CRT was observed in patients 
with lateral positioning of LV lead away from the 
apex. Position of right ventricular (RV) lead was 
indifferent [4].
Suboptimal LV lead location was reported in 
21% of patients with lack of CRT response [5].
Factors that influence LV lead position are usu-
ally periprocedual (adequate pacing threshold and 
sensing, lead stability and avoidance of diaphrag-
matic stimulation) [2]. Besides these conventional 
factors, knowledge of myocardial viability in the 
area of LV lead may help further optimize the LV 
lead location and response to CRT.
The aim of the study was to evaluate the influ-
ence of the myocardial contractile reserve during 
dobutamine infusion (as a measure of myocardial 
viability) in the area of LV electrode on the respon-
se rate and reverse remodeling of LV in patients 
receiving CRT.
Methods
The study prospectively enrolled 41 consecuti-
ve patients with LV dysfunction, LV ejection fraction 
(LVEF) < 35% and New York Heart Association 
(NYHA) class III with a QRS duration ≥ 120 ms. 
Patients with recent acute myocardial infarction 
(MI) (< 3 months), acute HF, myocardial revascu-
larization < 6 months before and with previously 
implanted pacemaker were excluded from the study.
Ischemic etiology of HF was defined as a hi-
story of MI and/or evidence of significant stenosis 
(≥ 70%) on coronary angiography. Coronary artery 
disease was present in 27 (51%) patients (Table 1). 
Non-ischemic etiology was defined as absence of 
significant stenosis on coronary angiography and/or 
absence of prior MI.
Biventricular pacemaker was implanted in all 
patients. Electrodes were placed by transvenous 
way (left subclavian vein). The atrial lead was 
placed in the right atrium. The RV lead was placed 
on the septal wall of the RV. The LV lead was posi-
tioned into a branch of a coronary sinus.
All patients gave informed consent to perform 
dobutamine stress echocardiography as part of 
a study.
Dobutamine stress echocardiography
Before the implantation standard echocardio-
graphic examination was performed in all patients 
(Siemens SC 2000, Mountain View, USA). LVEF 
using a biplane Simpson technique, LV end-systolic 
and end-diastolic diameter (LVESD, LVEDD), LV 
end-systolic and end-diastolic volume (LVESV, 
LVEDV) were recorded. In addition, dobutamine 
stress echocardiography was carried out.
Dobutamine was diluted in 400 mL 0.9% 
saline infusion and infused into antecubital vein 
in the incremental dosage. The infusion rate was 
gradually increased starting from 5 µg/kg/min up to 
20 µg/kg/min over 20 min. Baseline standard two-
-dimensional echocardiographic projections were 
obtained and stored in a digital cine-loop format for 
the off-line analysis.
Regional myocardial contractility  
assessment
Regional myocardial contractility was asses-
sed in the segment of LV where the stimulation 
electrode was located.
Table 1. Significant comorbidities and clinical 
parameters in patients receiving cardiac resyn-
chronization therapy (CRT) (n = 41).
Mean age [years] 61.9 ± 10.9
Men 33
Women 9
Mean LVEF [%] 26.3 ± 7.1
Mean QRS width [ms] 152.1 ± 22.3
LVEDD [mm] 6.4 ± 0.8
LVESD [mm] 5.6 ± 0.9
LVEDV [mL] 234.1 ± 71.7
LVESV [mL] 174.1 ± 59.8
Mean BMI [kg/m2] 25.94 ± 4.4
Mean plasma creatinine [µmol/L] 116 ± 43
Mean hemoglobin [g/L] 13.7 ± 1.6
Coronary artery disease 25 (60%)
Diabetes mellitus 24 (57%)
Arterial hypertension 33 (79%)
Atrial fibrillation 7 (16%)
LVEF — left ventricular ejection fraction; LVEDD — left ventricular 
end-diastolic diameter; LVESD — left ventricular end-systolic dia-
meter; LVEDV — left ventricular end-diastolic volume; LVESV — left 
ventricular end-systolic diameter; BMI — body mass index
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Contractility assessment was based on chan-
ges in LV strain during dobutamine infusion (20 µg/ 
/kg/min). Peak systolic radial strain was analyzed 
by speckle tracking echocardiography.
Viable myocardial segment was defined by an 
increase of the strain (deformation) during dobuta-
mine infusion. If no change or decrease in deforma-
tion of the myocardium was observed, myocardial 
segment was considered non-viable (Fig. 1).
Position of the left-ventricular electrode
Chest X-ray was carried out in all 41 patients 
on the second day following the pacemaker implan-
tation in 3 standard projections: anterior-posterior 
projection (AP), right-anterior oblique projection 
in 30 degrees (RAO 30) and left-anterior oblique 
projection in 60 degrees (LAO 60). Anatomic 
location of the stimulation electrode in the LV 
was assessed by 2 independent physicians. RAO 
30 projection was used to determine the position 
of the electrode in the frontal plane (Fig. 2). The 
position of the electrode in the frontal plane was 
classified as basal-, mid-, and apical-LV position.
In LAO 60 projection, the location of the elec-
trode in the frontal plane was determined using 
a scheme consisting of 17 segments (Figs. 3, 4).
Figure 1. Strain rate evaluation in the apical 4-chamber projection; A. Endocardium is manually traced in end-diastole 
in apical 4-chamber view. Vectors of myocardial strain are shown by small arrows. Arrows show direction and mag-
nitude of myocardial segment deformations; B. Myocardial strain curves in 6 different segments of left ventricle. 
Maximal extent of systolic deformation and the time to maximal deformation is detectable in each segment. Arrow 
points to the segment with the earliest (and the smallest) nadir of systolic deformation.
Figure 2. Position of the electrode in RAO 30 projection. Arrow shows the tip of the left ventricular electrode in the 
middle part of the left ventricle.
A B
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Follow-up
Patients were followed for 6 months. Follow-
-up included echocardiographic determination of the 
LVEF, LVESD, LVEDD, LVESV, LVEDV, as well as 
clinical assessment of the patient. Patients were 
classified as responders if they were alive, and an 
increase in LVEF ≥ 5% or decrease in end-systolic 
volume (ESV) ≥ 15% was observed at the follow-
-up. Other patients and patients who died during the 
follow-up period were classified as non-responders.
Statistical analysis
Continuous variables are expressed as mean ± 
± standard deviation. Categorical variables are 
expressed in frequencies and percentages. Data 
distribution was tested by Shapiro-Wilk test. 
Unpaired Student’s t-test was used to test diffe-
rences between responders and non-responders 
in parametric continuous variables and c2 test/ 
/Fischer’s exact test in normally distributed cate-
gorical parameters. Mann-Whitney test was used 
for non-parametric continuous data. Receiver ope-
rating characteristics (ROC) analysis was used to 
assess the usefulness of the myocardial viability in 
area of the LV electrode in the prediction of CRT 
response. P value < 0.05 was considered statisti-
cally significant.
Results
Responders and non-responders
Six months after pacemaker implantation 
24 (58%) patients were classified as responders and 
17 (42%) patients as non-responders based on echo-
cardiographic criteria, as mentioned above. Five pa-
tients from the non-responders group died because of 
a cardiovascular reason. One patient died because of 
the oncological disease and was excluded from the 
study. Two patients were lost during the follow-up.
There were no significant differences between 
group of responders and non-responders in clinical 
characteristics, laboratory parameters, and phar-
macological treatment (Table 2). A non-significant 
trend to higher level of creatinine and increased 
frequency of atrial fibrillation was observed in the 
non-responders group. In the responders LVEF 
significantly increased after 6 months of follow-up 
from 24.9 ± 7% to 36.5 ± 7.4% (p < 0.0001) and 
ESV decreased from 178 ± 54 mL to 129.8 ± 43 mL 
(p < 0.0001).
In the non-responder group, LVEF did not 
change significantly during the follow-up period 
Figure 3. Segments of the left ventricle.
Figure 4. Position of the electrode in LAO 60 projection in the same patient as in Figure 2. Arrow shows the tip of the 
electrode in inferolateral segment of the left ventricle.
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(28.2 ± 7% vs. 24.7 ± 5%, p > 0.1) (Fig. 5). Similar-
ly, ESV did not decrease in the non-responder group 
(168.6 ± 65 mL vs. 170.2 ± 51 mL, p > 0.1).
In the responder group, clinical improvement 
was also observed, expressed by decreased NYHA 
class, whereas NYHA class did not change in the 
non-responder group (– 0.77 ± 0.6 vs. 0.14 ± 0.6, 
p = 0.021) (Table 3).
Regional myocardial viability in the  
left-ventricular electrode area
Localization of LV electrode in the group of 
41 patients is shown in Table 4. The LV electrode 
was most frequently located in mid-inferolateral 
(one third of patients), mid-anterior and mid-
-anterolateral segments of the LV.
Table 3. Echocardiographic parameters and New York Heart Association (NYHA) classification before 
cardiac resynchronization therapy (CRT) and 6 months after CRT implantation in responders and non-
-responders.
Responders Non-responders P
Before CRT
EF [%] 24.9 ± 7.0 28.2 ± 7.1 NS
LVESV [mL] 178.0 ± 54.8 168.6 ± 65.8 NS
LVEDV [mL] 234.9 ± 62.5 233.0 ± 82.9 NS
LVESD [mm] 5.7 ± 0.8 5.4 ± 1.1 NS
LVEDD [mm] 6.5 ± 0.5 6.4 ± 0.9 NS
After 6-month follow-up 
D EF [%] 11.6 ± 8.1 –3.5 ± 5.3 < 0.0001*
D LVESV [mL] –48.2 ± 42.4 1.6 ± 22.0 < 0.0001*
D LVEDV [mL] –32.8 ± 45.7 –5.9 ± 38.1 0.0446*
D LVESD [mm] –0.1 ± 0.8 0.4 ± 0.7 NS
D LVEDD [mm] –0.1 ± 0.7 0.1 ± 0.7 NS
D NYHA –0.77 ± 0.6 0.14 ± 0.6 0.021*
*p < 0.05; EF — ejection fraction; LV — left ventricular; EDV — end-diastolic volume ESV — end-systolic volume; EDD — end-diastolic  
diameter; ESD — end-systolic diameter
Figure 5. Individual change in ejection fraction (EF) 
in patients who respond to cardiac resynchronization 
therapy (CRT).
Table 2. Clinical characteristics in responders and non-responders. All statistical significance: p = NS 
(non-significant).
Responders (n = 24) Non-responders (n = 17)
Mean age [years] 62.3 ± 11.3 61.4 ± 2.7
Men 17 (81%) 15 (79%)
Plasma creatinine [µmol/L] 107 ± 6 123 ± 16
Hemoglobin [g/L] 14.1 ± 1.8 13.3 ± 1.4
Body mass index [kg/m2] 25.1 ± 3.1 26.3 ± 5.2
Coronary artery disease 12 (50%) 13 (68%)
Diabetes mellitus 14 (64%) 10 (53%)
Arterial hypertension 16 (73%) 17 (89%)
Beta-blocker 20 (91%) 17 (89%)
Angiotensin converting enzyme inhibitor or sartan 19 (86%) 13 (68%)
Furosemide 19 (86%) 16 (84%)
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Table 4. Position of the left-ventricular electrode tip.
Left-ventricular  
electrode location 
Patient  
number (%)
Basal anterior segment 4 (10%)
Mid anterior segment 7 (17%)
Basal anterolateral segment 5 (12%)
Mid anterolateral segment 6 (15%)
Apical lateral segment 2 (5%)
Basal inferolateral segment 1 (2%)
Mid inferolateral segment 14 (34%)
Apical inferior segment 2 (5%)
Regional myocardial deformation in the area 
of the LV electrode tip was assessed by the strain 
analysis (Fig. 1). The myocardial deformation did 
not differ between responders and non-responders 
before dobutamine infusion (p = 0.0623).
During dobutamine infusion at a rate of 20 µg/ 
/kg/min, responders showed significant increase in 
the regional deformation (∆ strain) when compared 
to non-responders (2.14 ± 2.9% vs. –0.94 ± 1.74%, 
p = 0.042).
Patients with viable myocardium (i.e. with 
increased deformation during dobutamine sti-
mulation) in the area of LV electrode were more 
likely to be responders to CRT when compared 
to patients with LV electrode in non-viable seg-
ment of the LV (81% vs. 20%, p = 0.0002). They 
exhibited significant increase in LVEF and a trend 
(non-significant) to decreased LVESV (Table 5). 
ROC analysis showed that LV electrode localization 
in viable segment of the LV is a good predictor of 
CRT response (area under curve [AUC] 0.852, 
p < 0.0001) (Fig. 6).
Discussion
Viable myocardium is characterized by incre-
ased contractility in the setting of decreased 
metabolic demand and/or improved perfusion. 
The outcome of the CRT depends on myocardial 
Table 5. Influence of myocardial viability in the left ventricular (LV) electrode area on response to car-
diac resynchronization therapy.
Patients with viable LV 
electrode area
Patients with non-viable LV 
electrode area
P
D Deformation (strain) [%] 2.7 ± 2.6 – 1.7 ± 1.3 0.0001
Responders/non-responders 21/5 3/12 0.0002
D EF after 6 months [%] 8.8 ± 10.3 0.3 ± 6.4 0.0141
D LVESV after 6 months [mL] –35.7 ± 42.9 –13.5 ± 41.4 NS
LVESV — left ventricular end-systolic volume; EF — ejection fraction
viability. Interventricular and intraventricular 
resynchronization of the heart decreases intra-
mural stress and LV end-diastolic pressure and 
increases coronary perfusion. In the presence of 
viable myocardium, improved coronary perfusion 
augments the myocardial contractility and cardiac 
output [6, 7].
Myocardial viability can be measured as a glo-
bal contractile reserve during dobutamine infusion. 
An increase of 7.5% in LVEF during low dose dobu-
tamine infusion was reported as a predictor of the 
LV reverse remodeling and response to CRT [8].
Viability of the area directly under the LV sti-
mulation electrode is probably another important 
factor influencing the response to CRT. Implanta-
tion of the LV lead into the area of myocardial scar 
was suggested as one of the potential mechanisms 
of patients’ non-responsiveness to CRT. Cardiac 
pacing within the area of myocardial scar leads to 
Figure 6. Myocardial viability in area of the left ventricu-
lar electrode as a predictor of cardiac resynchronization 
therapy response; AUC — area under curve.
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prolonged and fragmented QRS complex and to 
electrical dyssynchrony [9]. Myocardial scar tissue 
is not excitable and reduces the extent of the LV 
myocardium which is responding to pacing stimulus 
[10]. Cardiac pacing in the area of myocardial scar is 
associated not only with the suboptimal response to 
CRT but also with increased risk of cardiovascular 
death or hospitalization for HF [11].
In the nuclear imaging study, using techne-
cium-99 m tetrofosmin single-photon emission 
computed tomography (SPECT), an extent and 
location of the myocardial scar was determined in 
51 patients with ischemic HF. Myocardial segments 
with tracer uptake of more than 75% were labeled 
as viable, segments with 50–75% of maximal tracer 
activity were considered to contain scar of small 
extent (non-transmural) and segments with less 
than 50% tracer uptake were considered to contain 
excessive scar (transmural infarction). Patients 
with transmural scar (n = 15, 29% of patients) did 
not show clinical improvement, reverse remodel-
ing of LV or increase in LV function after 6 months 
follow-up [12].
In another study of myocardial perfusion imag-
ing, using the method of SPECT, the average scar 
density in the segments in the vicinity of LV lead 
was lower in responders in comparison to non-
responders [13].
Different results were reported by Riedlbau-
chova et al. [14]. They assessed myocardial viability 
in CRT recipients with ischemic HF using a method 
of positron emission tomography. Simultaneous 
evaluation of dipyridamole-induced perfusion 
defect and fluorodeoxyglucose uptake allowed dif-
ferenciation between viable (hibernating) myocar-
dium and non-viable myocardium (scar). Clinical 
benefits were observed not only in patients with 
LV electrode localized in viable myocardium but 
also, in lesser extent, in patients with LV electrode 
positioned in the scar area. These benefits include 
LV remodeling in patients paced in the area of non-
-transmural scar and improvement of NYHA class 
in patients paced in the area of transmural scar.
Areas of myocardial fibrosis can be detected 
also by non-contact electroanatomical mapping 
as areas of slow conduction. Location of the LV 
electrode tip outside of slow conduction areas 
was associated with the significant hemodynamic 
improvement in patients with HF of ischemic and 
non-ischemic etiology undergoing CRT [15].
Myocardial contractility is a specific marker 
of myocardium viability. Myocardial deformation 
imaging can be used to determine myocardial 
contractility. Peak segmental myocardial strain is 
related to segmental viability [16]. Becker et al. 
[17] examined the impact of preserved viability in 
the area of LV lead on the reverse remodeling and 
functional status in 65 patients with CRT. Etiology 
of HF was ischemic in 46 patients and non-ischemic 
in 19 patients. They considered the LV segment 
viable when a peak circumferential strain assessed 
by speckle tracking imaging exceeded 11.1%. This 
value was reported to detect transmural MI defined 
by magnetic resonance imaging with the sensiti-
vity and specificity of about 70% [16]. Patients 
with the LV lead placed in a viable segment have 
greater increase in LVEF and decline in LVEDV 
than patients with LV electrode in non-viable 
segment. This difference was more pronounced 
in patients with ischemic HF than in patients with 
non-ischemic HF [17].
Longitudinal and circumferential strain rate 
during low dose dobutamine stress test determined 
by speckle tracking echocardiography can be used 
as a measure of myocardial viability and is able 
to predict functional recovery of the myocardial 
segment after revascularization [18].
Ran et al. [19] used adenosine as a different 
method of pharmacological stress testing du-
ring echocardiographic examination. Myocardial 
strain was calculated by the method of speckle 
tracking echocardiography. Myocardial viability 
was determined in all myocardial segments using 
radionuclide imaging of myocardial perfusion and 
myocardial metabolism. An increase in strain rate 
identified viable myocardial segments, while non-
-viable segments exhibited no increase in strain 
rate [19].
Results of our study are the same as results 
published by Ypenburg et al. [8]. They used 
a similar method for the determination of regional 
contractile reserve and reported an increase in 
peak strain in the LV lead region during low dose 
dobutamine stress test (10 µg/kg/min) in respond-
ers to CRT. In non-responders, regional contractile 
reserve was not present (no increase in strain was 
observed in the LV lead area).
In our study, we used the higher dose of dobu-
tamine infusion (20 µg/min) than in the previously 
mentioned study. Despite the more intensive beta-
adrenergic stimulation, we were not able to show 
an increase in myocardial contractility in LV lead 
area in non-responders to CRT. Our study confirms 
that myocardial viability in the paced area of LV 
is an important predictor of the response to CRT 
(AUC 0.852, p < 0.0001).
Loss of contractile tissue in the vicinity of the 
LV stimulation electrode due to fibrosis and scar 
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reduces the overall contractile force of the LV and 
alters appropriate sequence of LV contraction. In 
this way, it impedes the beneficial effect of CRT 
on the electrical and mechanical dyssynchrony in 
the failing heart.
Limitations of the study
The small amount of patients will require 
confirmation of the results on the larger study 
population. The follow-up period of 6 months is 
relatively short, the long-term effect of CRT needs 
to be assessed during longer follow-up period. In 
the present study, only radial myocardial strain 
was evaluated, determination of longitudinal and 
circumferential strain during dobutamine stress 
test could bring additional information.
Conclusions
The main result of the current study is that 
regional contractile reserve assessed by strain 
echocardiography during dobutamine infusion 
predicts the reverse remodeling of the LV and 
response to CRT.
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